908844-05-3Relevant academic research and scientific papers
In vitro and in silico studies of nitrobenzamide derivatives as potential anti-neuroinflammatory agents
Kulabas, Seda Savranoglu,Onder, Ferah Comert,Y?lmaz, Yakup Berkay,Ozleyen, Adem,Durdagi, Serdar,Sahin, Kader,Ay, Mehmet,Tumer, Tugba Boyunegmez
, p. 4655 - 4668 (2020)
Communicated by Ramaswamy H. Sarma.
PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells
Güng?r, Tu?ba,?nder, Ferah C?mert,Tokay, Esra,Gülhan, ünzile Güven,Hac?o?lu, Nelin,Tok, Tu?ba Ta?k?n,?elik, Ayhan,K??kar, Feray,Ay, Mehmet
, p. 383 - 400 (2019/04/01)
The use of nitroreductases (NTR) that catalyze the reduction of nitro compounds by using NAD(P)H in GDEPT (Gene-directed enzyme prodrug therapy) studies which minimize toxicity at healthy cells and increases concentration of drugs at cancer cells is remarkable. Discovery of new prodrug/NTR combinations is necessary to be an alternative to known prodrug candidates such as CB1954, SN23862, PR-104A. For this aim, nitro containing aromatic amides (A1-A23) were designed, synthesized, performed in silico ADMET and molecular docking techniques in this study. Prodrug candidates were studied on reduction potentials with Ssap-NtrB by HPLC system. Also, cyototoxic properties and prodrug ability of these amides were investigated using different cancer cell lines such as Hep3B and PC3. As a result of theoretical and biological studies, combinations of A5, A6 and A20 with Ssap-NtrB can be suggested as potential prodrugs/enzyme combinations at NTR based cancer therapy compared with CB1954/NfsB.
Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides
George, Tesmol G.,Johnsamuel, Jayaseharan,Delfin, Dawn A.,Yakovich, Adam,Mukherjee, Mitali,Phelps, Mitch A.,Dalton, James T.,Sackett, Dan L.,Kaiser, Marcel,Brun, Reto,Werbovetz, Karl A.
, p. 5699 - 5710 (2007/10/03)
N1-Phenyl-3,5-dinitro-N4,N4-di-n-propylsulfanilamide (1) and N1-phenyl-3,5-dinitro-N4,N4-di-n-butylsulfanilamide (2) show potent in vitro antimitotic activity against kinetoplastid parasites but display poor in vivo activity. Seventeen new dinitroaniline sulfonamide and eleven new benzamide analogs of these leads are reported here. Nine of the sulfonamides display in vitro IC50 values under 500 nM against African trypanosomes, and the most active antikinetoplastid compounds also inhibit the in vitro assembly of purified leishmanial tubulin with potencies similar to that of 2. While several of the potent compounds are rapidly degraded by rat liver S9 fractions in vitro, N1-(3-hydroxy)phenyl-3,5-dinitro-N4,N4-di-n-butylsulfanilamide (21) displays an IC50 value of 260 nM against African trypanosomes in vitro and is more stable than 2 in the in vitro metabolism assay.
